ScripGlaxoSmithKline Pharmaceuticals Ltd. is diving back into antibody-drug conjugate R&D with new partner Mersana Therapeutics, Inc. , paying $100m upfront to develop its preclinical ADC asset for HER-2
ScripWho: LifeMine Therapeutics/GlaxoSmithKline What: GSK gets discovery and development access to LifeMine’s Avatar-Rx genomically enabled discovery technology for up to three human therapeutic targets
ScripThe week before the annual J.P. Morgan Healthcare Conference always includes a bevy of new financings and the week before this year’s 11-14 January meeting kept up with the tradition with $1.67bn in v